51. Improvement of in vivo anticancer and antiangiogenic potential of thalidomide derivatives
- Author
-
Ana Cristina Lima Leite, Marcília Pinheiro da Costa, Gevânio Bezerra de Oliveira Filho, Adriana Andrade Carvalho, Francisco Vagnaldo Fechine-Jamacaru, Marcos Veríssimo de Oliveira Cardoso, Daniel de Araújo Viana, Patrícia Marçal da Costa, Manoel Odorico de Moraes, Claudia Pessoa, Paulo Michel Pinheiro Ferreira, and Suellen Melo Tibúrcio Cavalcanti
- Subjects
Angiogenesis Inhibitors ,Antineoplastic Agents ,Chick Embryo ,Pharmacology ,Toxicology ,Peripheral blood mononuclear cell ,Chorioallantoic Membrane ,Mice ,Structure-Activity Relationship ,Cell Movement ,In vivo ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Cytotoxic T cell ,Sarcoma 180 ,Cell Proliferation ,Toxicity ,Neovascularization, Pathologic ,biology ,Chemistry ,Melanoma ,Cancer ,Antitumor ,General Medicine ,Human cells ,medicine.disease ,Xenograft Model Antitumor Assays ,Angiogenesis inhibition ,Thalidomide ,biology.protein ,Female ,Antibody ,Phthalimide derivatives ,medicine.drug - Abstract
The strategy of antiangiogenic drugs is based on inhibiting formation of new blood vessels as alternative to limit cancer progression. In this work, we investigated the antitumor and antiangiogenic potential of eight thalidomide derivatives. Most of the molecules was not cytotoxic but 2a, 2d and 3d revealed weak antiproliferative activity on HL-60, Sarcoma 180 (S180) and normal peripheral blood mononuclear cells. Thalidomide, 2a and 2b were able to inhibit tumor growth (53.5%, 67.9% and 67.4%, respectively) in S180-bearing mice and presented moderate and reversible toxicity on liver, kidneys and spleens. Both analogs (2a and 2b) inhibited cell migration of endothelial (HUVEC) and melanoma cells (MDA/MB-435) at 50μg/mL. Immunohistochemistry labeling assays with CD-31 (PECAM-1) antibody showed microvascular density (MVD) was significantly reduced in thalidomide, 2a and 2b groups (30±4.9, 64.6±1.8 and 46.5±19.5%, respectively) (p
- Published
- 2015